SCHEMBL3282624

SCHEMBL3282624

O=C(O)c1c[nH]c(=O)c2cc(S(=O)(=O)NCCO)ccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.52
▸ POLB P06746 2/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ ALDH1A1 P00352 4/20 0.50
▸ PKM P14618 3/20 0.50
▸ CYP2C19 P33261 2/20 0.50
▸ GAA P10253 1/20 0.50
▸ HRH1 P35367 1/20 0.48
▸ CCR3 P51677 1/20 0.48
▸ KCNH2 Q12809 1/20 0.48
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ BRAF P15056 2/20 0.43
▸ NEK1 Q96PY6 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2923292 0.82 KDM4E (0.50) KDM4EPOLBTDP1L3MBTL1PKM
SCHEMBL2922360 0.78 KDM4E (0.56) KDM4EPOLBTDP1L3MBTL1ALDH1A1
SCHEMBL27615584 0.78 KDM4E (0.39) KDM4EPOLBTDP1L3MBTL1ALDH1A1
SCHEMBL3282678 0.78 PARG (0.50) KDM4ETDP1ALDH1A1HRH1CCR3
SCHEMBL2920920 0.77 KDM4E (0.54) KDM4EPOLBL3MBTL1ALDH1A1PKM
SCHEMBL2916302 0.77 KDM4E (0.54) KDM4EPOLBTDP1L3MBTL1ALDH1A1
SCHEMBL2922964 0.77 KDM4E (0.54) KDM4EPOLBTDP1L3MBTL1CYP2C19
SCHEMBL2913348 0.74 KDM4E (0.50) KDM4EPOLBTDP1L3MBTL1ALDH1A1
SCHEMBL8293406 0.73 CYP2C19 (0.57) ALDH1A1PKMCYP2C19GAAMEN1
SCHEMBL2916325 0.72 KDM4E (0.54) KDM4EPOLBTDP1L3MBTL1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
US-7709500-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-05-04 — — US disclosed
US-20050107428-A1 Chemical compounds ASTRAZENECA AB (SE) 2005-05-19 — — US disclosed
EP-1478624-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2004-11-24 — — EP disclosed
WO-2003068743-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2003-08-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107428-A1 Chemical compounds CCR10, CCR3, CXCR5 KDM4E 1685/4885POLB 3604/4885TDP1 4817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback